RxDoctor Payments Data

Brian Pachter, DO

Internal Medicine · Miami Beach, FLNPI 1750571048

Payments from drug & device makers

$9,469in general payments, 2019–2025

Across 423 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$955
  • Bayer$823
  • Takeda Pharmaceuticals U.S.A., Inc.$771
  • Lilly USA, LLC$724
  • AbbVie$620
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,462100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,469 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$100,556
Medicare patients
211
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$109,328
FarxigaDapagliflozin Propanediol79$58,762
OzempicSemaglutide54$51,393
EliquisApixaban89$45,507
XareltoRivaroxaban50$31,939
JanuviaSitagliptin Phosphate43$22,155
RybelsusSemaglutide14$20,762
Repatha SureclickEvolocumab21$17,195
KerendiaFinerenone12$11,318
ProcritEpoetin Alfa11$9,359
MyrbetriqMirabegron16$8,454
Rosuvastatin Calcium293$4,088
Atorvastatin Calcium344$3,392
ClopidogrelClopidogrel Bisulfate117$2,925
Levothyroxine Sodium211$2,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$724$109,32896 claims
Novo NordiskOzempic, Rybelsus$1,456$72,15568 claims
AstraZenecaFarxiga$955$58,76279 claims
PfizerEliquis$614$45,50789 claims
Johnson & JohnsonXarelto, Procrit$134$41,29861 claims
BayerKerendia$823$11,31812 claims
Astellas Pharma US IncMyrbetriq$34$8,45416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →